Clinical Trial Detail

NCT ID NCT03554109
Title QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements yes
Sponsors NantKwest, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel

Cyclophosphamide + Doxorubicin + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST